A new study of patients at an urban cancer center points to a potentially serious problem that may limit the impact of clinical cancer care — undiagnosed depression. Among the 40 percent of patients at the center who were diagnosed with depression, three in four had not previously been told they were depressed. Female patients and disabled patients also were more likely to be depressed, according to research presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

Radiation therapy following mastectomy for intermediate-stage, high-risk breast cancer can be shortened from five to three weeks while maintaining tumor control rates in the breast and surrounding region that are equivalent to conventional treatment, according to new research. The findings were presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

September 28, 2017 — Barco will use NeoLogica’s RemotEye Suite universal viewing solution software to enrich and simplify radiology and breast imaging display demonstrations in the United States and Canada. The software allows all types of patient images – including 3-D mammography – to be displayed in one easy-to-use application.

In a new phase III trial report, recurrence-free and overall survival rates for women with stage I-II high-risk endometrial cancer were not superior following vaginal cuff brachytherapy plus chemotherapy when compared with pelvic radiation therapy. Risks of pelvic and para-aortic nodal recurrence and frequency of short-term side effects were greater for the brachytherapy-chemotherapy approach. High completion rates for each treatment arm suggest that both therapies are well-tolerated by patients. Findings from the report from the National Clinical Trial Network group, NRG Oncology, were presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego.

To improve value and minimize patient exposure to ionizing radiation, healthcare providers’ use of medical imaging must be prudent and appropriate. The cornerstone of value-based imaging is technology that provides broad access to patient reports and images, enhancing communications among physicians and with the patient while protecting patient data. This is the role of the enterprise viewer.

 Fill out the information below to download white paper.

When putting an enterprise imaging system in place, many health systems use a zero-footprint viewer to access patient reports and images. Houston Medical Imaging (HMI) in Houston uses a zero-footprint viewer to help not only physicians but patients as well.

Researchers have found that disconnections of brain areas involved in attention and visual processing may contribute to visual hallucinations in individuals with Parkinson’s disease, according to a new study published online in the journal Radiology. The disconnected brain areas seen on functional magnetic resonance imaging (fMRI) may be valuable in predicting the development of visual hallucinations in patients with Parkinson’s disease.

Toshiba Medical announced it will highlight several of its latest vascular and interventional imaging solutions at the 2017 Annual Meeting of the Radiological Society of North America (RSNA), Nov. 26-Dec. 1 in Chicago.

September 27, 2017 — A new study finds Medicaid expansion enacted as part of the Patient Protection and Affordable Care Act (ACA) improved care coverage for cancer patients receiving radiation therapy and potentially decreased healthcare disparities.

For certain patients with oropharyngeal cancer caused by the human papilloma virus (HPV), an aggressive reduction of radiation therapy after surgery may provide excellent cancer control while simultaneously reducing post-treatment side effects, according to research presented at the 59th Annual Meeting of the American Society of Radiation Oncology (ASTRO). Reducing radiation therapy post-surgery may also improve quality of life and lower treatment costs. Patients in the phase II clinical trial received half the standard radiation dose but achieved equally high cure rates at two years following treatment.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now